Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.73 |
| ▸ | GSK3B | P49841 | 2/20 | 0.63 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987081 | 0.90 | PTPN1 (0.75) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL27993965 | 0.87 | PTPN1 (0.58) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL22130998 | 0.86 | PTPN1 (0.71) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL29249309 | 0.82 | KMT2A (0.62) | PTPN1GSK3BCES1NR4A2NPC1 | |
| SCHEMBL3569892 | 0.82 | PTPN1 (0.66) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL313164 | 0.82 | PLOD2 (0.70) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL5060636 | 0.82 | MMP1 (0.67) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL28972896 | 0.82 | PTPN1 (0.65) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL28972894 | 0.82 | PTPN1 (0.65) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL2865544 | 0.81 | MAPT (0.65) | PTPN1GSK3BMMP1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112513021-A | ROR gamma antagonist and application thereof in medicine | 广东东阳光药业有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3148972-B1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-9682938-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-3148972-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | Cardioxyl Pharmaceuticals Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015183839-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-12-03 | — | — | US | disclosed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110098301-A1 | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders | BAYER HEALTHCARE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2005098925-A1 | TECHNIQUES PROMOTING ADHESION OF POROUS LOW K FILM TO UNDERLYING BARRIER LAYER | APPLIED MATERIALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005035507-A2 | 4-AMINOPYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0412933-B1 | Coating compositions | CIBA GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| US-5183842-A | Mixture of ketoacid and amine with film-forming binder, curing | CIBA-GEIGY CORPORATION (US) | 1993-02-02 | — | — | US | disclosed |
| US-5128396-A | Corrosion inhibiting primers on metallic substrates | CIBA-GEIGY CORPORATION (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0412933-A1 | Coating compositions | CIBA-GEIGY AG (CH) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | PTPN1 1899/4885GSK3B 1652/4885MMP1 3735/4885 |
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | TYMP, DPYD, CCNA2 | PTPN1 3053/4885GSK3B 2749/4885MMP1 4742/4885 |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | PTPN1 2727/4885GSK3B 563/4885MMP1 4388/4885 |
| US-20110098301-A1 | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders | DPYD, TYMP, TYMS | PTPN1 2935/4885GSK3B 2423/4885MMP1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.